Role of FcγRs in Antibody-Based Cancer Therapy
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/82_2019_150
Reference94 articles.
1. Abès R et al (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6):926–934
2. Albanell J, Baselga J (1999) Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer Drugs Today (Barc) 35:931–946
3. Amiri-Kordestani L et al. (2014a) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer Clin Cancer Res 20:4436–4441 https://doi.org/10.1158/1078-0432.ccr-14-0012
4. Amiri-Kordestani L et al. (2014b) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer Clin Cancer Res 20:5359–5364 https://doi.org/10.1158/1078-0432.ccr-14-1268
5. Barnhart BC, Quigley M (2017) Role of Fc-FcgammaR interactions in the antitumor activity of therapeutic antibodies. Immunol Cell Biol 95:340–346. https://doi.org/10.1038/icb.2016.121
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering;Nature Communications;2023-11-08
2. Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy;Scientific Reports;2022-12-29
3. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma;Cells;2022-11-13
4. CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition;Cancer Cell;2022-11
5. “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients;Frontiers in Oncology;2022-07-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3